Latest Conference Articles

Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.

With so many cancer treatment options now available, clinicians may still fall short in understanding what’s important to patients.

Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.

An international study of nearly 2,000 patients with renal cell carcinoma exposed many unmet needs across all stages of disease.

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.

Jennifer King, from the GO2 Foundation for Lung Cancer, discussed what patients can do to help address the stigma associated with lung cancer.

Researchers adapted a screening tool to help treat the whole person during cancer care.

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.

The phase 3 POLO trial is the first randomized study to establish a biomarker-driven approach in the treatment of metastatic pancreatic cancer.

Two oncology dietitians weigh in on the results of a recent study that show a low-fat diet rich in fruits, vegetables and grains can reduce the risk of dying from breast cancer.

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

Eva Moon shares nine habits for keeping a sense of humor when the going gets rough.

One expert shares advice for opening the line of communication between patients and health care providers, as well as their partners.

One family shares their experience with the discovery of a BRCA mutation, and how they discussed it among one another.

Exercise and nutrition are essential to improving a variety of facets revolving around the continuum of cancer — from prevention to diagnosis and treatment to survivorship care.

Although individuals may have concerns about enrolling in a study, their involvement may lead to new discoveries.

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

Eva Moon, a writer, musician and performing artist, discusses her genetic mutation and how it changed the direction of her life.

Audra Moran, president and CEO of the Ovarian Cancer Research Fund Alliance, discusses the support available for caregivers of women with ovarian cancer.

Investigators are learning how to take a tumor biopsy from a patient, grow small tumors called organoids in the lab, and test cancer treatments on them to see which work best.

Thanks to targeted drugs and evolving research, women who experience recurrences of ovarian cancer have more treatment options than they did in the past..